A framework for advanced technology medicines from the perspective of community pharmacists; with or without technology
DOI:
https://doi.org/10.1590/s2175-97902022e20654Keywords:
Advanced technology medicines, Nanomedicines, Biologic drugs, 3D-printed drugs, Community pharmacistsAbstract
Nowadays, the number of medicines manufactured using advanced technologies such as biotechnology, nanotechnology, and 3D printing is increasing along with the accelerated pace of technological change. Evaluating high technology medicines from the perspective of community pharmacists is important for the quality of the pharmacy practice. The aim is to analyze the knowledge, attitude, and behavior of community pharmacists regarding advanced technology medicines and to examine the social and ethical aspects from the pharmacist’s perspective. A face-to-face cross-sectional survey was conducted with each of the 879 community pharmacists in Istanbul using a stratified sampling method. In this context, the gaps in pharmacists’ knowledge of high technology medicines were determined. It has been found that the pharmacists’ level of knowledge and willingness to learn new technologies differs according to the current education levels of the pharmacists and diversity in patient profiles. The pharmacists should close the knowledge gaps and update their information about medicines that are manufactured via the implementation of advanced technologies. The more pharmacists adapt to technology, the better guidance they can offer to society. This will also ensure that communication between the pharmacist and the patient to be built on trust, and significantly improve pharmacy practice.
Downloads
References
Adé A, Bourdon O, Bussières JF. A survey of pharmacists’ knowledge and views of biosimilars in Quebec and France. Ann Pharm Fr. 2017;75(4):267-275.
Alhnan MA, Okwuosa TC, Sadia M, Wan KW, Ahmed W, Arafat B. Emergence of 3D printed dosage forms: opportunities and challenges. Pharm Res. 2016;33(8):1817-1832.
Alomari M, Mohamed FH, Basit AW, Gaisford S. Personalised dosing: printing a dose of one’s own medicine. Int J Pharm. 2015;494(2):568-577.
Aquino RP, Barile S, Grasso A, Saviano M. Envisioning smart and sustainable healthcare: 3D Printing technologies for personalized medication. Futures. 2018;103:35-50.
Araújo MR, Sa-Barreto LL, Gratieri T, Gelfuso GM, Cunha-Filho M. The digital pharmacies era: How 3D printing technology using fused deposition modeling can become a reality. Pharmaceutics. 2019;11(3):128.
Assali M, Shakaa A, Abu-Hejleh S, Abu-Omar R, Karajeh N, Ajory N, et al. A cross-sectional study of the availability and pharmacist’s knowledge of nano-pharmaceutical drugs in Palestinian hospitals. BMC Health Serv Res. 2018;18(1):250.
Baines D, Nørgaard LS, Rossing C. The Fourth Industrial Revolution: Will it change pharmacy practice? Res Social Adm Pharm. 2020;16(9):1279-1281.
Bottini M, Rosato N, Gloria F, Adanti S, Corradino N, Bergamaschi A, et al. Public optimism towards nanomedicine. Int J Nanomedicine. 2011;6:3473.
Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2016;33(12):2160-2172.
Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med. 2006;56(5):307-311.
Giuliani R, Tabernero J, Cardoso F, McGregor KH, Vyas M, Vries EGE, et al. Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open. 2019;4(2):e000460.
Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102-112.
Maclurcan DC. Southern roles in global nanotechnology innovation: perspectives from Thailand and Australia. Nanoethics. 2009;3(2):137-156.
Norman J, Madurawe RD, Moore CM, Khan MA, Khairuzzaman. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv Drug Deliv Rev. 2017;108:39-50.
O’Callaghan J, Griffin BT, Morris JM, Bermingham M. Knowledge of adverse drug reaction reporting and the pharmacovigilance of biological medicines: a survey of healthcare professionals in Ireland. BioDrugs. 2018;32(3):267-280.
Pawłowska I, Pawłowski L, Krzyżaniak N, Kocić I . Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals. BioDrugs . 2019;33(2):183-191.
Timmermans J, Zhao Y, van den Hoven J. Ethics and nanopharmacy: Value sensitive design of new drugs. Nanoethics . 2011;5(3):269-283.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
